Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GlucoTrack, Inc. (NASDAQ:GCTK) announced a $10 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner on April 17, 2023. The funds are intended to support the company's mission of developing non-invasive glucose monitoring devices for diabetes patients. Founded in 2001 and based in Or Yehuda, Israel, GlucoTrack is focused on providing an alternative to traditional glucose measurement methods, thereby improving the quality of life for diabetics and pre-diabetics. The company aims to enhance its product offerings and expand its market reach with the new capital raised from this offering.